Survival of node positive penile cancer patients who relapsed following definitive treatment
BAUS ePoster online library. Crawford R. 11/10/20; 304259; P6-6
Mr. Ruairidh Crawford
Mr. Ruairidh Crawford
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
Survival of node positive penile cancer patients who relapsed following definitive treatment

Crawford R1, Afshar M1, Toomey D1, Ager M1, Ayres B1, Watkin N1
1St George's Hospital, London, United Kingdom

Introduction:
Survival of node positive penile cancer (SCCp) patients who relapse on surveillance has not been widely reported. We recognise that patients who relapse tend to be early in surveillance and progress quickly. The aim of this study is to quantify time to nodal/distant relapse and survival.

Patients and Methods:
A retrospective analysis was performed on a prospectively collected database of all SCCp cases from 2005 to 2017. Patients with node positive disease on surveillance were included. Relapse free survival was calculated from last nodal surgery to evidence of relapse and survival from time of relapse to death. Kaplan Meier curves were plotted with log-rank test to assess differences in survival curves.

Results:
244 men with node positive disease of 1110 SCCp were identified. 73 relapsed. 10 pN1 disease, 9 pN2 and 54 pN3. Median relapse free survival for pN1 was 5 months, pN2 5 months and pN3 6 months. Median survival following relapse was pN1 6.5 months, pN2 8 months and pN3 6 months. Treatment of relapse data was available for 65 patients. 45 patients received treatment, predominantly chemotherapy/radiotherapy; their median survival was 8 months. 20 patients who relapsed were unsuitable for treatment and palliated; their median survival was 2.5 months.

Conclusions:
Relapse in node positive SCCp has a highly unfavourable prognosis, with no difference between the initial nodal staging and overall survival. Palliative treatments may have a role for symptomatic control only. Surveillance strategies may need optimisation to reflect the rapidity and progression within the first 12 months.
Survival of node positive penile cancer patients who relapsed following definitive treatment

Crawford R1, Afshar M1, Toomey D1, Ager M1, Ayres B1, Watkin N1
1St George's Hospital, London, United Kingdom

Introduction:
Survival of node positive penile cancer (SCCp) patients who relapse on surveillance has not been widely reported. We recognise that patients who relapse tend to be early in surveillance and progress quickly. The aim of this study is to quantify time to nodal/distant relapse and survival.

Patients and Methods:
A retrospective analysis was performed on a prospectively collected database of all SCCp cases from 2005 to 2017. Patients with node positive disease on surveillance were included. Relapse free survival was calculated from last nodal surgery to evidence of relapse and survival from time of relapse to death. Kaplan Meier curves were plotted with log-rank test to assess differences in survival curves.

Results:
244 men with node positive disease of 1110 SCCp were identified. 73 relapsed. 10 pN1 disease, 9 pN2 and 54 pN3. Median relapse free survival for pN1 was 5 months, pN2 5 months and pN3 6 months. Median survival following relapse was pN1 6.5 months, pN2 8 months and pN3 6 months. Treatment of relapse data was available for 65 patients. 45 patients received treatment, predominantly chemotherapy/radiotherapy; their median survival was 8 months. 20 patients who relapsed were unsuitable for treatment and palliated; their median survival was 2.5 months.

Conclusions:
Relapse in node positive SCCp has a highly unfavourable prognosis, with no difference between the initial nodal staging and overall survival. Palliative treatments may have a role for symptomatic control only. Surveillance strategies may need optimisation to reflect the rapidity and progression within the first 12 months.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies